Client Login Portal
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    Labaton Sucharow
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Contact Us
    • Knowledge Network
    • Client Login
    • Search
    • addthis
    • link : Client Login
    • knowledge network
    Labaton Sucharow
    • News & Events
      • Press Room
      • Published
      • Events
    • Digital Library
      • Videos
      • Podcasts
      • Webinars
    • News & Events
      • Press Room
      • Published
      • Events
      • The Liaison
    • Digital Library
      • Videos
      • Podcasts
      • Webinars

    Actavis at 4: Pay-for-Delay Lawsuits Receding

    Law360
    June 20, 2017

    Gregory Asciolla shares his thoughts on the fourth anniversary of SCOTUS’ Actavis decision on pay-for-delay lawsuits

    In its 2013 decision in Federal Trade Commission v. Actavis, the U.S. Supreme Court supported the Federal Trade Commission’s view that pharmaceutical patent dispute settlements that transfer consideration from a brand drug company to a generic should be subject to antitrust scrutiny, triggering a wave of pay-for-delay litigation.

    Law360 noted that firms specializing in representing plaintiffs in high-profile class actions against pharmaceutical companies have lost their desire to pursue pay-for-delay litigation. However, according to Firm partner Gregory Asciolla, drugmakers are still making those agreements.

    Pay-for-delay cases have their challenges but no more than other kinds of complex antitrust litigation, said Asciolla, whose firm has brought a substantial number of such cases against brand and generic manufacturers. Law in the area is still developing in the wake of Actavis, and there are still novel issues being raised in the cases, he said.

    It is too soon to say whether the drop in potentially anticompetitive reverse payment settlements is part of a consistent downward trend or if it simply represents a temporary dip in the agreements, Asciolla said. Rulings by circuit courts that have somewhat clarified when settlements run afoul of antitrust law could embolden companies to pursue further agreements, he said.

    In any case, plaintiffs firms will not be shy about bringing pay-for-delay suits against drug companies in the future, Asciolla said.

    "As long as the agreements exist, and after investigating and looking closely at them we determine there are potentially anticompetitive effects, we certainly will have an appetite to pursue litigation," he said.

    Useful Links

    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Center

    Our Locations

    footer-list-map_icon New York
    140 Broadway
    New York, NY 10005
    212-907-0700

    footer-list-map_icon Delaware
    222 Delaware Avenue, Suite 1510
    Wilmington, DE 19801
    302-573-2540

    Useful Links

    footer-list-map_icon Washington, D.C.
    1050 Connecticut Avenue, NW, Suite 500
    Washington, D.C. 20036
    212-907-0700

    Stay Connected

    • Facebook
    • Twitter
    • LinkedIn
    Labaton Sucharow
    • Attorney Advertising Disclaimer
    • Privacy Policy
    • Transparency in Coverage Rule
    • labaton.com
    • Labaton Sucharow All Rights Reserved 2023

    Attorney Advertising Disclaimer

    The materials appearing on this website are provided for informational purposes only and do not constitute legal advice. You should not take action based upon this information without consulting legal counsel. This site is not intended to create an attorney-client relationship. The hiring of a lawyer is an important decision that should not be based solely upon any single source of information, including advertising on this website. You may ask us to send you further information about us, and we urge you to review other sources of information about us.